Qingyu Xiu

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 468 citations

Medicine, Oncology, Pharmacology +14

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 120 citations · Full text

Medicine, Oncology, Pharmacology +14

YKL-40 Induces IL-8 Expression from Bronchial Epithelium via MAPK (JNK and ERK) and NF-κB Pathways, Causing Bronchial Smooth Muscle Proliferation and Migration

Hao Tang, Yu Sun, Zhaoquan Shi et al. · The Journal of Immunology · 2012 · 119 citations

Life Sciences, Cell Biology, Immunology +14

YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E

Hao Tang, Ye Sun, Benhua LI et al. · European Respiratory Journal · 2010 · 101 citations · Full text

Life Sciences, Immunology, Internal Medicine +12